第22回あわじ感染と免疫国際フォーラム

○Masaharu Iwasaki^1,2,3,4 (1. Laboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University (Japan), 2. Center for Infectious Disease Education and Research, Osaka University (Japan), 3. Center for Advanced Modalities and Drug Delivery System, Osaka University (Japan), 4. RNA Frontier Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University (Japan))

○Alessandro Pardini^1,2,3, Dominik Alexander Rothen^1,2,3, Pascal Sigfried Krenger^1,2,3, Anne-Cathrine Sarah Vogt^1,2,3, Romano Josi^1,2,3, Monique Vogel^1,2, Manfred Kopf⁴, Martin Fabian Bachmann^1,2,5 (1. Department of BioMedical Research, University of Bern, Bern, (Switzerland), 2. Department of Rheumatology and Immunology, University Hospital Bern, Bern, (Switzerland), 3. Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, (Switzerland), 4. Institute of Molecular Health Sciences, ETH Zurich, Zurich (Switzerland), 5. Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, (UK))

○Ming Te Yeh¹, Raul Andino² (1. Osaka University (Japan), 2. University of California San Francisco (United States of America))

○Shuntaro Shimizu^1,2,3,4, Tomoya Hayashi^1,2,3, Koji Sakamoto⁵, Naozumi Hashimoto⁶, Kouji Kobiyama^1,2,3, Hideo Negishi^1,2,3, Burcu Temizoz^1,2,3, Cevayir Coban^2,3,7, Ken Ishii^1,2,3 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan (Japan), 2. International Vaccine Design Center, IMSUT, Tokyo, Japan (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan (Japan), 4. Department of Chemistry, Chemical Engineering & Life Science, Yokohama National University, Kanagawa, Japan (Japan), 5. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan (Japan), 6. Department of Respiratory Medicine, Fujita Health University, Nagoya, Japan (Japan), 7. Division of Malaria Immunology, Department of Microbiology and Immunology, IMSUT, Tokyo, Japan (Japan))

○Masayuki Kuraoka¹ (1. Duke University (United States of America))

○Hidetaka Akita^1,2 (1. Graduate School of Pharmaceutical Sciences, Tokoku University (Japan), 2. Center for Advanced Modalities and DDS, Osaka University (Japan))